CoChat

The fibrin-derived γ377-395 peptide inhibits microglia activation and suppresses relapsing paralysis in central nervous system autoimmune disease

Open access

The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.

Abstract

Perivascular microglia activation is a hallmark of inflammatory demyelination in multiple sclerosis (MS), but the mechanisms underlying microglia activation and specific strategies to attenuate their activation remain elusive. Here, we identify fibrinogen as a novel regulator of microglia activation and show that targeting of the interaction of fibrinogen with the microglia integrin receptor Mac-1 (alpha(M)beta(2), CD11b/CD18) is sufficient to suppress experimental autoimmune encephalomyelitis in mice that retain full coagulation function. We show that fibrinogen, which is deposited perivascularly in MS plaques, signals through Mac-1 and induces the differentiation of microglia to phagocytes via activation of Akt and Rho. Genetic disruption of fibrinogen-Mac-1 interaction in fibrinogen-gamma(390-396A) knock-in mice or pharmacologically impeding fibrinogen-Mac-1 interaction through intranasal delivery of a fibrinogen-derived inhibitory peptide (gamma(377-395)) attenuates microglia activation and suppresses relapsing paralysis. Because blocking fibrinogen-Mac-1 interactions affects the proinflammatory but not the procoagulant properties of fibrinogen, targeting the gamma(377-395) fibrinogen epitope could represent a potential therapeutic strategy for MS and other neuroinflammatory diseases associated with blood-brain barrier disruption and microglia activation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1084/jem.20061931

Cites

72 of 72 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Fibrinogen directly activates microglia resulting in cytoskeletal rearrangements and increased phagocytosis. (A) IsoB4/DAPI immunostained microglia cultured on immobilized fibrinogen have increased cell body size adopting an amoeboid morphology (right). Untreated primary microglia show small cell bodies and thin, bipolar processes (left). LPS-treated cells show activated morphology characterized by cell body swelling (middle). Bar, 26 μm; inset, 21 μm. (B) Quantitation of microglia activation reveals a dramatic increase upon fibrinogen stimulation. (C) Fibrinogen-stimulated microglia showed increased phagocytosis of fluorescent Escherichia coli as compared with untreated microglia. LPS served as a positive control. (D) Deconvolution microscopy of primary microglia revealed significant rearrangements of the cytoskeleton upon treatment with fibrinogen. Microglia were stained with antibodies to actin and β-tubulin in red, and the nucleus was stained blue with DAPI. Bar, 4.4 μm.
Figure 1. Fibrinogen directly activates microglia resulting in cytoskeletal rearrangements and increased phagocytosis. (A) IsoB4/DAPI immunostained microglia cultured on immobilized fibrinogen have increased cell body size adopting an amoeboid morphology (right). Untreated primary microglia show small cell bodies and thin, bipolar processes (left). LPS-treated cells show activated morphology characterized by cell body swelling (middle). Bar, 26 μm; inset, 21 μm. (B) Quantitation of microglia activation reveals a dramatic increase upon fibrinogen stimulation. (C) Fibrinogen-stimulated microglia showed increased phagocytosis of fluorescent Escherichia coli as compared with untreated microglia. LPS served as a positive control. (D) Deconvolution microscopy of primary microglia revealed significant rearrangements of the cytoskeleton upon treatment with fibrinogen. Microglia were stained with antibodies to actin and β-tubulin in red, and the nucleus was stained blue with DAPI. Bar, 4.4 μm.CC BY-NC-SA · PubMed Central
Figure 2. Fibrinogen directly activates microglia via the Mac-1 integrin receptor. (A) Fibrinogen-induced morphologic activation of microglia is blocked by the addition of a rat anti-CD11b neutralizing antibody (M1/70). Rat IgG (control) did not change the effects of fibrinogen in microglia activation. Bar, 39 μm; inset, 17 μm. (B) Quantitation of microglia activation reveals that the Mac-1 neutralizing antibody blocks fibrinogen-induced activation but not LPS activation of microglia. (C) Increased microglia phagocytosis upon fibrinogen stimulation is blocked by the addition of a PI3K inhibitor (LY294002) and diminished in the presence of a CD11b neutralizing antibody. A control anti-TLR4 or IgG showed no reduction in fibrinogen-stimulated phagocytosis. (D) Western blots show increased active RhoA and Akt activation upon fibrinogen stimulation of microglia. In both assays, LPS served as a positive control. (E) Confocal microscopy demonstrates the spatial interaction between CD11b+ cells (green) and fibrin (red) in spinal cords from PLP139-151–immunized mice. (F) Confocal double immunofluorescence shows fibrin (green) surrounding an activated microglia (red) in a human early demyelinating plaque of acute MS. Bars: E, 6.7 μm; F, 15 μm.
Figure 2. Fibrinogen directly activates microglia via the Mac-1 integrin receptor. (A) Fibrinogen-induced morphologic activation of microglia is blocked by the addition of a rat anti-CD11b neutralizing antibody (M1/70). Rat IgG (control) did not change the effects of fibrinogen in microglia activation. Bar, 39 μm; inset, 17 μm. (B) Quantitation of microglia activation reveals that the Mac-1 neutralizing antibody blocks fibrinogen-induced activation but not LPS activation of microglia. (C) Increased microglia phagocytosis upon fibrinogen stimulation is blocked by the addition of a PI3K inhibitor (LY294002) and diminished in the presence of a CD11b neutralizing antibody. A control anti-TLR4 or IgG showed no reduction in fibrinogen-stimulated phagocytosis. (D) Western blots show increased active RhoA and Akt activation upon fibrinogen stimulation of microglia. In both assays, LPS served as a positive control. (E) Confocal microscopy demonstrates the spatial interaction between CD11b+ cells (green) and fibrin (red) in spinal cords from PLP139-151–immunized mice. (F) Confocal double immunofluorescence shows fibrin (green) surrounding an activated microglia (red) in a human early demyelinating plaque of acute MS. Bars: E, 6.7 μm; F, 15 μm.CC BY-NC-SA · PubMed Central
Figure 3. Fibrin depletion using ancrod reverses relapsing paralysis and reduces microglia activation in EAE. (A) Immunofluorescence of control (left) and fibrin-depleted (right) spinal cord with antibodies against fibrinogen (red) and CD11b (green). Activated CD11b+ cells colocalize with fibrin deposition in the control spinal cord (yellow). Bar, 8.4 μm. (B) Clinical scores of PLP139-151–immunized mice. Fibrin depletion begins after the first paralytic episode. Fibrin-depleted mice (red circles; n = 8) did not develop first or second relapses as compared with control mice (black circles; n = 10). (C) Rotarod motor strength and coordination test. Fibrin-depleted mice outperformed immunized control untreated mice on day 25 after immunization. Data are represented as the mean clinical score and are mean ± SEM.
Figure 3. Fibrin depletion using ancrod reverses relapsing paralysis and reduces microglia activation in EAE. (A) Immunofluorescence of control (left) and fibrin-depleted (right) spinal cord with antibodies against fibrinogen (red) and CD11b (green). Activated CD11b+ cells colocalize with fibrin deposition in the control spinal cord (yellow). Bar, 8.4 μm. (B) Clinical scores of PLP139-151–immunized mice. Fibrin depletion begins after the first paralytic episode. Fibrin-depleted mice (red circles; n = 8) did not develop first or second relapses as compared with control mice (black circles; n = 10). (C) Rotarod motor strength and coordination test. Fibrin-depleted mice outperformed immunized control untreated mice on day 25 after immunization. Data are represented as the mean clinical score and are mean ± SEM.CC BY-NC-SA · PubMed Central
Figure 4. Fibγ390-396A mice have reduced clinical scores and microglia activation in EAE. (A) Clinical scores of MOG35-55–immunized mice. Fibγ390-396A mice (blue triangles; n = 29) show statistically significant lower clinical scores (*, P < 0.01) than FibγWT control mice (black squares; n = 28). (B) Individual clinical scores from Fibγ390-396A and FibγWT mice on days 20 (average clinical score, 3.3 ± 0.22 for FibγWT [n = 19] vs. 2.1 ± 0.32 for Fibγ390-396A [n = 20]; P < 0.01) and 31 after immunization (average clinical score, 2.8 ± 0.25 for FibγWT [n = 15] vs. 1.5 ± 0.23 for Fibγ390-396A [n = 20]; P < 0.001). (C) Histological analysis of spinal cord sections stained with hematoxylin/eosin revealed increased inflammation in the FibγWT mice versus the Fibγ390-396A mice. (D) Survival curve of Fibγ390-396A and FibγWT mice after MOG35-55 immunization. Fibγ390-396A had a greater survival rate than the FibγWT mice. (E) Rotarod analysis of Fibγ390-396A and FibγWT mice on day 13. Fibγ390-396A significantly outperformed their wild-type counterparts in a behavioral test designed to assess motor skill function. n = 7 mice per group. **, P < 0.05. (F) Increased activation of IsoB4+ cells in FibγWT mice as compared with Fibγ390-396A mice. Bar, 58 μm. Data are represented as the mean clinical score and are mean ± SEM.
Figure 4. Fibγ390-396A mice have reduced clinical scores and microglia activation in EAE. (A) Clinical scores of MOG35-55–immunized mice. Fibγ390-396A mice (blue triangles; n = 29) show statistically significant lower clinical scores (*, P < 0.01) than FibγWT control mice (black squares; n = 28). (B) Individual clinical scores from Fibγ390-396A and FibγWT mice on days 20 (average clinical score, 3.3 ± 0.22 for FibγWT [n = 19] vs. 2.1 ± 0.32 for Fibγ390-396A [n = 20]; P < 0.01) and 31 after immunization (average clinical score, 2.8 ± 0.25 for FibγWT [n = 15] vs. 1.5 ± 0.23 for Fibγ390-396A [n = 20]; P < 0.001). (C) Histological analysis of spinal cord sections stained with hematoxylin/eosin revealed increased inflammation in the FibγWT mice versus the Fibγ390-396A mice. (D) Survival curve of Fibγ390-396A and FibγWT mice after MOG35-55 immunization. Fibγ390-396A had a greater survival rate than the FibγWT mice. (E) Rotarod analysis of Fibγ390-396A and FibγWT mice on day 13. Fibγ390-396A significantly outperformed their wild-type counterparts in a behavioral test designed to assess motor skill function. n = 7 mice per group. **, P < 0.05. (F) Increased activation of IsoB4+ cells in FibγWT mice as compared with Fibγ390-396A mice. Bar, 58 μm. Data are represented as the mean clinical score and are mean ± SEM.CC BY-NC-SA · PubMed Central
Figure 5. The fibrin-derived γ377-395 peptide inhibits microglia activation. (A) Microglia activation upon fibrinogen stimulation is attenuated in the presence of γ377-395. Bar, 33 μm; inset, 29 μm. (B) Quantitation of microglia activation reveals that γ377-395 diminishes fibrinogen-stimulated microglia activation but has no effect on LPS activation. (C) Treatment of microglia with γ377-395 blocks fibrinogen-induced Akt activation in vitro. LPS activation of Akt is unaffected by γ377-395 treatment.
Figure 5. The fibrin-derived γ377-395 peptide inhibits microglia activation. (A) Microglia activation upon fibrinogen stimulation is attenuated in the presence of γ377-395. Bar, 33 μm; inset, 29 μm. (B) Quantitation of microglia activation reveals that γ377-395 diminishes fibrinogen-stimulated microglia activation but has no effect on LPS activation. (C) Treatment of microglia with γ377-395 blocks fibrinogen-induced Akt activation in vitro. LPS activation of Akt is unaffected by γ377-395 treatment.CC BY-NC-SA · PubMed Central
Figure 6. The fibrin-derived γ377-395 peptide suppresses EAE. (A) Clinical scores from γ377-395 peptide–vaccinated mice. Mice were immunized with γ377-395 peptide before EAE induction with PLP139-151 peptide. Vaccinated mice (blue triangles; n = 15) had significantly reduced clinical scores as compared with control mice (black squares; n = 15). (B) Clinical scores from PLP139-151–immunized mice where the γ377-395 peptide was administered every day intranasally after the peak of the initial paralytic episode. γ377-395–treated mice (blue triangles; n = 14) did not show a relapse at approximately day 30 as compared with the controls (black squares; n = 13). *, P < 0.05; **, P < 0.01. Data are represented as the mean clinical score and are mean ± SEM. Immunostaining for Mac-3 and iNOS (inset) on day 30 after immunization shows dramatic reduction of microglia activation in the γ377-395 peptide–treated mice after EAE induction (D) when compared with control (C). Bar, 20 μm; inset, 10 μm. (E) Quantitation shows a twofold reduction in Mac-3 (P < 0.05) and a 4.2-fold reduction in iNOS (P < 0.01) after γ377-395 peptide treatment, whereas there are no major differences in T cell infiltration.
Figure 6. The fibrin-derived γ377-395 peptide suppresses EAE. (A) Clinical scores from γ377-395 peptide–vaccinated mice. Mice were immunized with γ377-395 peptide before EAE induction with PLP139-151 peptide. Vaccinated mice (blue triangles; n = 15) had significantly reduced clinical scores as compared with control mice (black squares; n = 15). (B) Clinical scores from PLP139-151–immunized mice where the γ377-395 peptide was administered every day intranasally after the peak of the initial paralytic episode. γ377-395–treated mice (blue triangles; n = 14) did not show a relapse at approximately day 30 as compared with the controls (black squares; n = 13). *, P < 0.05; **, P < 0.01. Data are represented as the mean clinical score and are mean ± SEM. Immunostaining for Mac-3 and iNOS (inset) on day 30 after immunization shows dramatic reduction of microglia activation in the γ377-395 peptide–treated mice after EAE induction (D) when compared with control (C). Bar, 20 μm; inset, 10 μm. (E) Quantitation shows a twofold reduction in Mac-3 (P < 0.05) and a 4.2-fold reduction in iNOS (P < 0.01) after γ377-395 peptide treatment, whereas there are no major differences in T cell infiltration.CC BY-NC-SA · PubMed Central
Figure 7. The fibrin-derived γ377-395 peptide does not affect in vivo coagulation or fibrin polymerization. In vivo clotting time (A) and prothrombin times (B) were assayed in the presence of 30 μg γ377-395 peptide, the dose administered in vivo daily, and 90 μg γ377-395 peptide. Neither dose affected blood clotting times. (C) In vitro fibrin polymerization was examined in the presence of the γ377-395 peptide. GPRP, a known inhibitor of fibrin formation, significantly attenuated fibrin formation, whereas the γ377-395 peptide had no effect on fibrin polymerization.
Figure 7. The fibrin-derived γ377-395 peptide does not affect in vivo coagulation or fibrin polymerization. In vivo clotting time (A) and prothrombin times (B) were assayed in the presence of 30 μg γ377-395 peptide, the dose administered in vivo daily, and 90 μg γ377-395 peptide. Neither dose affected blood clotting times. (C) In vitro fibrin polymerization was examined in the presence of the γ377-395 peptide. GPRP, a known inhibitor of fibrin formation, significantly attenuated fibrin formation, whereas the γ377-395 peptide had no effect on fibrin polymerization.CC BY-NC-SA · PubMed Central
Figure 8. Proposed model for the role of fibrin-induced activation of microglia in inflammatory demyelination. BBB disruption permits the leakage of fibrinogen, the high affinity ligand for Mac-1, in the CNS parenchyma. Fibrinogen is converted to fibrin and functions as the spatial signal to induce local activation of microglia via activation of the Mac-1 integrin receptor and induction of signaling pathways downstream of Mac-1, such as Akt and Rho, resulting in phagocytosis that could determine the extent of tissue damage in inflammatory demyelination.
Figure 8. Proposed model for the role of fibrin-induced activation of microglia in inflammatory demyelination. BBB disruption permits the leakage of fibrinogen, the high affinity ligand for Mac-1, in the CNS parenchyma. Fibrinogen is converted to fibrin and functions as the spatial signal to induce local activation of microglia via activation of the Mac-1 integrin receptor and induction of signaling pathways downstream of Mac-1, such as Akt and Rho, resulting in phagocytosis that could determine the extent of tissue damage in inflammatory demyelination.CC BY-NC-SA · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 72 references

Cited by

Items 301–344 of 344

Metadata

Authors
Adams, R. A., Bauer, J., Flick, M. J., Sikorski, S. L., Nuriel, T., Lassmann, H., Degen, J. L., & Akassoglou, K.
Affiliations
  • University of California San Diego (US)
  • Medical University of Vienna (AT)
  • University of Cincinnati (US)
Venue
The Journal of Experimental Medicine
Published
2007-03-05
Volume
204
Issue
3
Pages
571-582
ISSN
  • 0022-1007 (ISSN-L)
  • 1540-9538
OpenAlex
W2142424019
Cited by
335
References
72
Citations by year
2026: 11 · 2025: 16 · 2024: 19 · 2023: 22 · 2022: 16 · 2021: 27 · 2020: 21 · 2019: 16 · 2018: 21 · 2017: 16 · 2016: 19 · 2015: 18 · 2014: 15 · 2013: 17 · 2012: 18
FWCI
11.33
Type
journal article
Language
en
Open access
Licence
cc-by-nc-sa
Locations
  • The Journal of Experimental Medicine (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by-nc-sa)
Funders
National Institute of Neurological Disorders and Stroke (R01NS052189, P30NS047101, R01NS051470)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Hematology › Blood properties and coagulation
Keywords
fibrinogen, microglial activation, Mac-1, CD11b/CD18, multiple sclerosis, experimental autoimmune encephalomyelitis, inflammatory demyelination, Akt signaling, Rho GTPase signaling, blood-brain barrier disruption, neuroinflammation
MeSH terms
Amino Acid Sequence, Animals, Cells, Cultured, Female, Fibrin, Fibrinogen, Mice, Inbred C57BL, Molecular Sequence Data, Peptide Fragments, Macrophage-1 Antigen, Microglia, Multiple Sclerosis, Relapsing-Remitting, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.